- Home
- ORKA vs HDL Comparison
ORKA vs HDL Comparison
Compare ORKA & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ORKA | HDL |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.1B |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | ORKA | HDL |
|---|---|---|
| Price | $30.18 | $17.38 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $45.22 | N/A |
| AVG Volume (30 Days) | ★ 412.0K | 2.3K |
| Earning Date | 11-12-2025 | 11-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | ★ $820,865,000.00 |
| Revenue This Year | N/A | $11.19 |
| Revenue Next Year | N/A | $13.37 |
| P/E Ratio | ★ N/A | $438.76 |
| Revenue Growth | N/A | ★ 8.02 |
| 52 Week Low | $5.49 | $16.30 |
| 52 Week High | $32.28 | $30.00 |
Technical Indicators
Market Signals| Indicator | ORKA | HDL |
|---|---|---|
| Relative Strength Index (RSI) | 55.78 | 46.17 |
| Support Level | $29.38 | $16.70 |
| Resistance Level | $32.28 | $17.49 |
| Average True Range (ATR) | 1.63 | 0.29 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 62.17 | 41.72 |
Price Performance
Historical ComparisonAbout ORKA Oruka Therapeutics Inc.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.